Alba Galan
Montreal, QC H3T1E2, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Selective inhibitors of the TrkC.T1 receptor reduce retinal inflammation and delay neuronal death in a model of retinitis pigmentosa.
Journal: PNAS nexus
Published: June 28, 2024
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
Journal: The Journal of clinical investigation
Published: May 01, 2024
GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer.
Journal: Frontiers in oncology
Published: December 30, 2022
Therapeutic Neuroprotection by an Engineered Neurotrophin that Selectively Activates Tropomyosin Receptor Kinase (Trk) Family Neurotrophin Receptors but Not the p75 Neurotrophin Receptor.
Journal: Molecular pharmacology
Published: April 14, 2021
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
Journal: The Journal of clinical investigation
Published: May 28, 2020
Alternative Splicing of a Receptor Intracellular Domain Yields Different Ectodomain Conformations, Enabling Isoform-Selective Functional Ligands.
Journal: iScience
Published: February 19, 2020
Antagonism of proNGF or its receptor p75NTR reverses remodelling and improves bladder function in a mouse model of diabetic voiding dysfunction.
Journal: Diabetologia
Published: February 19, 2020
Neuroprotection: Pro-survival and Anti-neurotoxic Mechanisms as Therapeutic Strategies in Neurodegeneration.
Journal: Frontiers in cellular neuroscience
Published: January 31, 2019
Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy.
Journal: Cell chemical biology
Published: August 02, 2018
The route of administration influences the therapeutic index of an anti-proNGF neutralizing mAb for experimental treatment of Diabetic Retinopathy.
Journal: PloS one
Published: January 26, 2018
Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy.
Journal: Investigative ophthalmology & visual science
Published: June 02, 2017
Last Updated: 09/26/2026